+

WO2000042959A1 - Unite posologique compacte pour administration orale de principe actif pharmacologique - Google Patents

Unite posologique compacte pour administration orale de principe actif pharmacologique Download PDF

Info

Publication number
WO2000042959A1
WO2000042959A1 PCT/US2000/001534 US0001534W WO0042959A1 WO 2000042959 A1 WO2000042959 A1 WO 2000042959A1 US 0001534 W US0001534 W US 0001534W WO 0042959 A1 WO0042959 A1 WO 0042959A1
Authority
WO
WIPO (PCT)
Prior art keywords
dosage unit
active agent
buccal
testosterone
individual
Prior art date
Application number
PCT/US2000/001534
Other languages
English (en)
Inventor
Virgil A. Place
Original Assignee
Place Virgil A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Place Virgil A filed Critical Place Virgil A
Priority to AU26236/00A priority Critical patent/AU2623600A/en
Priority to CA002359582A priority patent/CA2359582A1/fr
Priority to EP00904484A priority patent/EP1162929A4/fr
Publication of WO2000042959A1 publication Critical patent/WO2000042959A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • This invention relates generally to the field of buccal drug delivery, i.e., to the transmucosal administration of pharmacologically active agents through the buccal mucosa.
  • the invention provides a novel dosage unit for administering a drug through the buccal mucosa, and additionally provides therapeutic methods involving use of the buccal dosage units.
  • the invention finds utility in a variety of contexts, including, but not limited to, delivery of steroid drugs in hormone replacement therapy, in the treatment of androgen- responsive disorders, in the treatment of male sexual dysfunction, and as contraceptive agents, and delivery of macromolecular drugs such as proteins, peptides, peptide fragments and polysaccharides.
  • buccal drug delivery i.e., administration of a drug through the buccal mucosa
  • buccal drug delivery systems Prior to the present invention, however, buccal drug delivery systems have proved to be problematic.
  • a non-erodible backing layer is typically present that can lodge in the pharynx if a buccal tablet or patch is inadvertently swallowed.
  • Prior buccal tablets or patches have also been relatively large and have tended to move about within a patient's mouth, both factors resulting in patient discomfort.
  • More recently described buccal dosage forms are somewhat complicated to manufacture, insofar as distinct layers with different chemical and physical properties need to be made and incorporated into a single dosage form. See, for example, U.S. Patent Nos.
  • the dosage unit adheres well to the buccal mucosa, is small enough so as not to cause patient discomfort, and completely hydrolyzes within the mouth, i.e., gradually and completely bioerodes throughout the drug delivery period.
  • the dosage unit may be used to administer any one of a number of pharmacologically active agents.
  • Androgens are the hormones that cause most of the masculinizing changes that occur in males during puberty. Harrison 's Principles of Internal Medicine, 12 th Edition (New York, NY: McGraw Hill, Inc., 1991). Testosterone is secreted by the testis and adrenal gland and is the main androgen present in the plasma of men. See, e.g., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9 th Edition (New York, NY: McGraw Hill, Inc., 1996). As explained in the aforementioned text, the concentration of testosterone in the plasma of human males is relatively high throughout several periods of life, including the period of embryonic development in which the male phenotypic differentiation takes place, the neonatal period, and during adult sexual life.
  • testosterone concentrations in the plasma Prior to puberty, concentrations of testosterone are in the plasma are low, on the order of 20 nanograms/deciliter (ng/dl) or less. In adults, plasma testosterone concentrations range from about 300 to 1000 ng/dl, and the rate of production is 2.5 to 11 mg per day. Approximately 40% of the testosterone is bound to sex hormone-binding protein and about 2% is free, or unbound; the remainder is bound to albumin and other proteins. Testosterone is secreted in a pulsatile manner, so that normal testosterone levels fluctuate within a circadian pattern during the course of a day. See, e.g., Goodman & Gilman's, supra.
  • testosterone levels begin to rise in boys, reaching adult levels by the age of about seventeen. See, e.g., Harrison 's Principles of Internal Medicine, supra.
  • the rise in testosterone levels during puberty catalyzes a variety of anatomical and developmental changes, including maturation of the accessory organs of male reproduction, development of facial hair, regression of the scalp line, appearance of pubic hair, and increased growth of muscle and connective tissue.
  • Altered testicular steroid levels can result from hypothalamic- pituitary disorders or testicular defects. For example, failure of the testis to develop or function, resulting in hypogonadism, may result from a deficiency of gonadotropin or from primary testicular failure.
  • hypogonadism occurs prior to puberty, development of secondary sexual characteristics will be impaired or absent. In the adult, hypogonadism results in osteopenia, regression of the prostate and seminal vesicles, reduction in the volume of semen, and loss of muscle mass, strength and vigor. Loss of steroid production also results in psychological depression and reduction or absence of the libido, both of which are associated with sexual dysfunction. See, e.g., Harrison 's Principles of Internal Medicine, supra.
  • Testosterone is well absorbed after its oral administration but is quickly degraded during its passage through the liver and intestine. Therefore, it is not possible to achieve therapeutic blood levels of testosterone via oral administration. 17 ⁇ -alkylated derivatives of testosterone can be administered orally and are resistant to hepatic degradation, but are not recommended for clinical use due to their high potential for hepatoxicity.
  • Bhasin et al. (1997) J. ofClin. Endoc. and Met. 82(1 ):3.
  • Transdermal delivery of testosterone has been described, but requires flux enhancement with skin permeation enhancers. As noted above, skin permeation enhancers frequently result in irritation and sensitization of the skin. and.
  • the buccal drug delivery systems of the present invention are, however, new and completely unsuggested by the art.
  • Applicant's invention is premised on the discovery that a simple, compact, completely hydrolyzable buccal dosage unit, containing, in a preferred embodiment, only the pharmacologically active agent to be administered and an excipient, provides for highly efficient, highly effective drug delivery.
  • Still additional objects of the invention include methods for effecting male contraception, providing male hormone replacement therapy, treating male sexual dysfunction, and treating androgen-responsive disorders, by using the dosage units of the invention to administer an androgenic agent such as testosterone through
  • a pharmaceutical composition in the form of a simple, compact buccal dosage unit comprising a therapeutically effective amount of a pharmacologically active agent in a bioerodible polymeric carrier, wherein the carrier is such that it enables the dosage unit to adhere to the buccal mucosa. Following application to the buccal mucosa, gradual and complete erosion of the unit occurs over a predetermined time period, thus providing drug delivery throughout that time period.
  • the dosage unit contains only the active agent to be administered and the polymeric carrier.
  • other components particularly a lubricant, may be incorporated to facilitate manufacture of the unit or if otherwise found to be necessary or desirable.
  • the buccal dosage units are typically far smaller than conventional buccal delivery systems—the present tablets are on the order of 5-20 mg, typically 10-15 mg ⁇ and do not require a plurality of excipients, disintegrants, adhesives, or the like, nor are fragrances or permeation enhancers necessary. Accordingly, the novel dosage units are more comfortable than conventional systems because of their compact size. The units also tend to stay in place after being affixed to the buccal mucosa. While the dosage units are designed to erode and thus deliver the active agent over a time period in the range of about 4 hours to 24 hours, 20- to 24-hour dosage units are preferred for administration of an androgenic agent.
  • the preferred androgenic agent is testosterone, or a pharmacologically acceptable derivative, analog, ester or salt thereof.
  • a method for administering a pharmacologically active agent to a mammalian individual using the aforementioned buccal dosage units, to treat any disorder, condition, disease or dysfunction for which the active agent is indicated.
  • An androgenic agent may be administered, for example, to treat sexual dysfunctional in a mammalian male, to provide male hormone replacement therapy, to treat androgen-responsive disorders (e.g., primary or secondary hypogonadism), or the like.
  • the active agent is administered by affixing a dosage unit as provided herein to the buccal mucosa of the individual undergoing treatment, and allowing the dosage unit to remain in place until erosion thereof and thus drug delivery is complete.
  • the dosage unit is affixed to the upper gum area in a region defined as extending from the first bicuspid on the left to the first bicuspid on the right; an alternative preferred location for the dosage unit is the inner lip area opposing the aforementioned upper gum area.
  • a further embodiment of the invention relates to a kit to assist an individual in buccal drug administration.
  • the kit includes the following components: a buccal dosage unit comprising a pharmacologically active agent and a bioerodible polymeric carrier; a container housing the dosage unit prior to use; and written instructions for carrying out administration of the active agent for the intended therapeutic purpose.
  • Figure 1 is a graph illustrating testosterone and dihydrotestosterone plasma levels as a function of time, following administration of either a placebo or a Tl-1 or T2-1 buccal testosterone tablet, as described in Example 3.
  • Figure 2 is a graph illustrating free testosterone plasma levels as a function of time, following administration of either a placebo or a Tl-1 or T2-1 buccal testosterone tablet, also as described in Example 3.
  • Figure 3 is a graph illustrating estradiol plasma levels as a function of time, following administration of either a placebo or a Tl-1 or T2-1 buccal testosterone tablet, also as described in Example 3.
  • Figure 4 schematically illustrates a preferred embodiment of a buccal dosage unit according to the invention.
  • Figure 5 schematically illustrates an alternative embodiment of a buccal dosage unit according to the invention.
  • Figure 6 schematically illustrates a second alternative embodiment of a buccal dosage unit according to the invention.
  • Figure 7 illustrates placement of the buccal dosage unit in the preferred location in the oral cavity, on the upper gum area in a region defined as extending from the first bicuspid on the left to the first bicuspid on the right.
  • drug or “pharmacologically active agent” or “active agent” as used herein refer to a compound or composition of matter which, when administered to an organism
  • a "macromolecular” drug as used herein generally refers to a drug having a molecular weight greater than about 250 Daltons, typically greater than about 500 Daltons, and is normally a peptide, peptide fragment, protein or polysaccharide.
  • uccal drug delivery is meant delivery of a drug by passage of a drug through the buccal mucosa into the bloodstream.
  • buccal drug delivery is effected herein by placing the buccal dosage unit on the upper gum or opposing inner lip area of the individual undergoing drug therapy.
  • Poration enhancement or “permeation enhancement” as used herein relates to an increase in the permeability of the buccal mucosal tissue to a pharmacologically active agent, i.e., so that the rate at which the drug permeates through the mucosal tissue is increased.
  • Excipients or “vehicles” as used herein refer to any excipients or vehicles suitable for buccal drug administration, and include any such materials known in the art, e.g., any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is nontoxic and which does not interact with other components of the composition in a deleterious manner.
  • an “effective” or “therapeutically effective” amount of a drug or pharmacologically active agent is meant a nontoxic but sufficient amount of the drug or agent to provide the desired effect.
  • An “effective" amount of a permeation enhancer as used herein means an amount that will provide the desired increase in the rate at which an active agent passes through the tissue of the buccal mucosa.
  • Compact refers to a buccal dosage unit that is preferably no larger than about 5 mm in diameter and 2 mm in height, so that the unit occupies at most about 40 mm 3 , typically weighs less than about 40 mg (preferably 5 to 20 mg, more preferably 10 to 15 mg), and has a contact surface area of no more than 20 mm 2 .
  • electrodes and “bioerodible” as used herein refer to a compound or composition that hydrolyzes upon contact with the buccal mucosa.
  • an androgen-responsive disorder includes any disease or condition that may be treated by administration of androgens as provided herein.
  • a particular example of an androgen-responsive disorder is hypogonadism.
  • the term "sexual dysfunction” is generally used to mean erectile dysfunction in mammalian males, and is intended to include any and all types of erectile dysfunction, including: vasculogenic, neurogenic, endocrinologic and psychogenic impotence ("impotence” is used here in its broadest sense to indicate an inability a periodic or consistent inability to achieve or sustain an erection of sufficient rigidity for sexual intercourse; see U.S. Patent No.
  • treating and “treatment” as used herein refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediaton of damage.
  • the present method of "treating" an androgen-responsive disorder encompasses both prevention of the disorder in a predisposed individual and treatment of the disorder in a clinically symptomatic individual.
  • treatment of sexual dysfunction encompasses both prevention and treatment of sexual dysfunction.
  • a pharmaceutical composition is provided in the form of a buccal dosage unit for the administration of a pharmacologically active agent.
  • the dosage unit comprises (a) a therapeutically effective amount of the active agent and (b) a bioerodible polymeric carrier as will be described in detail below.
  • the dosage unit is fabricated so as to erode gradually over a predetermined time period, wherein drug delivery is provided essentially throughout.
  • the time period is typically in the range of 4 hours to 24 hours; that is, for a 4-hour unit, erosion will occur throughout a 4-hour period and be complete at the 4- hour point, while for a 24-hour unit, erosion will occur throughout a 24-hour period and be complete at the 24-hour point.
  • the buccal dosage unit may further comprise a lubricant to facilitate manufacture, e.g., magnesium stearate or the like. Additional components that may be included in the buccal dosage unit, but are neither required nor preferred, are flavorings, permeation enhancers, diluents, binders, and the like.
  • a buccal drug delivery system the novel dosage unit avoids the disadvantages encountered with oral drug administration, e.g., degradation of the agent by fluids present in the gastrointestinal tract and/or first-pass inactivation in the liver.
  • the unit is not associated with the discomfort encountered with larger, conventional buccal drug delivery systems.
  • the units are convenient in that the wearer need replace a spent unit only once or twice daily, i.e., with 24-hour or 12-hour systems, respectively; a 12-hour unit to be applied once in the morning and once in the evening is optimal.
  • the unit contains only the active agent and the polymeric carrier —manufacture of the dosage form is straightforward and economical.
  • the pharmacologically active agents that may be used in conjunction with the invention are typically drugs that have low oral bioavailability and cannot, therefore, be administered orally.
  • Potent drugs i.e., drugs that are effective at low dosages are preferred, so that a smaller quantity of active agent can be used; drugs that require higher dosages, necessitating a larger dosage unit, should be avoided.
  • "Potent" drugs in the present context are drugs that are effective at a dosage of less than 15 mg in a 24-hour period.
  • suitable pharmacologically active agents for use herein include, but are not limited to: anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations; anesthetics; anorexics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihistamines; antihypertensives; antiinflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; anticholinergics; calcium channel blockers; cardiovascular preparations; central nervous system stimulants; cough and cold preparations, including decongestants; diuretics; growth factors; growth hormones; hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; psychostimulants; sedatives; sympathomimetics; vas
  • Specific drugs and drug types that can be effectively delivered using the buccal dosage units of the invention include, but are not limited to, steroids such as androgens, estrogens, progestins and corticosteroids; macromolecular drugs such as proteins, peptides, peptide fragments, and polysaccharides; nicotine; and fentanyl.
  • steroids such as androgens, estrogens, progestins and corticosteroids
  • macromolecular drugs such as proteins, peptides, peptide fragments, and polysaccharides
  • nicotine and fentanyl.
  • Suitable androgens that may be used in the formulations of the present invention include, but are not limited to: the naturally occurring androgens and derivatives thereof, including androsterone, androsterone acetate, androsterone propionate, androsterone benzoate, androstenediol, androstenediol-3 -acetate, androstenediol-17-acetate, androstenediol-3 , 17-diacetate, androstenediol- 17-benzoate, androstenediol-3-acetate- 17- benzoate, androstenedione. ethylestrenol, oxandrolone, nandrolone phenpropionate.
  • Testosterone per se is a particularly preferred androgenic agent for use in conjunction with the present invention.
  • the aforementioned testosterone esters are commercially available or may be readily prepared using techniques known to those skilled in the art or described in the pertinent literature. (Generally, the 17-hydroxyl group of the testosterone molecule is caused to react with a suitable organic acid under esterifying conditions, such conditions typically involving the use of a strong acid such as sulfuric acid, hydrochloric acid, or the like, and a temperature sufficient to allow the reaction to proceed at reflux.)
  • suitable estrogens that may be administered using the dosage units of the invention include synthetic and natural estrogens such as: estradiol (i.e., l,3,5-estratriene-3,17 ⁇ -diol, or " ⁇ -estradiol”) and its esters, including estradiol benzoate, valerate, cypionate, heptanoate, decanoate, acetate and diacetate; 17 ⁇ -estradiol; ethynyl
  • Estradiol and ethynylestradiol are particularly preferred synthetic estrogenic agents for use in conjunction with the present invention.
  • Suitable progestins for use in the buccal drug delivery units of the invention include, but are not limited to, acetoxypregnenolone, allylestrenol, anagestone acetate, chlormadinone acetate, cyproterone, cyproterone acetate, desogestrel, dihydrogesterone, dimethisterone, ethisterone (17 ⁇ -ethynyltestosterone), ethynodiol diacetate, flurogestone acetate, gestadene, hydroxyprogesterone, hydroxyprogesterone acetate, hydroxyprogesterone caproate, hydroxymethylprogesterone, hydroxymethylprogesterone acetate, 3-ketodesogestrel, levonorgestrel, lynestrenol, medrogestone,
  • Progesterone, cyproterone acetate, norethindrone, norethindrone acetate and levonorgestrel are preferred progestins.
  • Macromolecular drugs are active agents having a molecular weight of at least about 250 Daltons, normally at least about 500 Daltons, and are typically proteins, peptides, peptide fragments, or polysaccharides.
  • a preferred polysaccharide to be delivered buccally using the present dosage units is heparin.
  • such macromolecular drugs may be delivered using the dosage units of the invention without regard to how the drugs are prepared, i.e., they may be naturally occurring, chemically synthesized or recombinantly produced.
  • Still other active agents that can be administered using the buccal dosage units of the invention include nicotine and fentanyl.
  • the active agent may be incorporated into the present dosage units and thus administered in the form of a pharmaceutically acceptable derivative, analog, ester or salt, or the agent may be modified by appending one or more appropriate functionalities to enhance selected biological properties such as penetration through the mucosal tissue.
  • esters are preferred relative to salts or other derivatives. Preparation of esters involves functionalization of hydroxyl and/or carboxyl groups which may be present, as will be appreciated by those skilled in the art of pharmaceutical chemistry and drug delivery. Esters can be reconverted to the free acids, if desired, by using conventional hydrogenolysis or hydrolysis procedures.
  • suitable pharmaceutically acceptable salts can be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry and described, for example, by J. March, Advanced Organic Chemistry: Reactions, Mechanisms and Structure, 4th Ed. (New York: Wiley-Interscience, 1992). Acid addition salts are prepared from an active agent in the free base form (e.g., compounds having a neutral -NH 2 group) using conventional means, involving reaction with a suitable acid.
  • Suitable acids for preparing acid addition salts include both organic acids, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like, as well as inorganic acids, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • organic acids e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic
  • An acid addition salt may be reconverted to the free base by treatment with a suitable base.
  • Preparation of basic salts of acid moieties which may be present are prepared in a similar manner using a pharmaceutically acceptable base such as sodium, hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, magnesium hydroxide, trimethylamine, or the like.
  • a pharmaceutically acceptable base such as sodium, hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, magnesium hydroxide, trimethylamine, or the like.
  • the drug may be incorporated into the present dosage units either as the racemate or in enantiomerically pure form.
  • the quantity of active agent in the buccal dosage unit will depend on the potency of the agent and the intended dosage, which, in turn, is dependent on the particular individual undergoing treatment, the specific indication, and the like. Suitable doses of specific active agents will be known to those skilled in the art, or may be deduced from the literature in combination with the teaching of the present disclosure. By way of example, a typical daily dosage of testosterone for treatment of sexual dysfunction or other indications as discussed herein is in the range of about 4 to about 10 mg.
  • the dosage unit will generally contain from approximately 40 wt.% to about 80 wt.% active agent, preferably on the order of 50 wt.% to about 75 wt.% active agent. The remainder of the composition is comprised of a carrier as will be described in detail below.
  • the carrier comprises a polymer having sufficient tack to ensure that the dosage unit adheres to the buccal mucosa for the necessary time period, i.e., the time period during which drug is to be delivered to the buccal mucosa.
  • the polymeric carrier is gradually "bioerodible," i.e., the polymer hydrolyzes at a predetermined rate upon contact with moisture.
  • the polymeric carrier is preferably sticky when moist, but not when dry, for convenience in handling.
  • the weight average molecular weight (M w ) of the polymer be in the range of approximately 4,000 to 1,000,000, more preferably in the range of approximately 100,000 to 1,000,000.
  • M w weight average molecular weight
  • any polymeric carriers can be used that are pharmaceutically acceptable, provide both a suitable degree of adhesion and the desired drug release profile, and are compatible with the drug to be administered and any other components that may be present in the buccal dosage unit.
  • the polymeric carriers comprise hydrophilic (water-soluble and water- swellable) polymers that adhere to the wet surface of the buccal mucosa.
  • examples of polymeric carriers useful herein include acrylic acid polymers and co, e.g., those known as "carbomers” (Carbopol®, which may be obtained from B.F. Goodrich, is one such polymer).
  • polymers include, but are not limited to: hydrolyzed polyvinylalcohol; polyethylene oxides (e.g., Sentry Poly ox® water soluble resins, available from Union Carbide); polyacrylates (e.g., Gantrez®, which may be obtained from GAF); vinyl polymers and copolymers; polyvinylpyrrolidone; dextran; guar gum; pectins; starches; and cellulosic polymers such as hydroxypropyl methylcellulose, (e.g., Methocel®, which may be obtained from the Dow Chemical Company), hydroxypropyl cellulose (e.g., Klucel®, which may also be obtained from Dow), hydroxypropyl cellulose ethers (see, e.g., U.S.
  • the carrier may also comprise two or more suitable polymers in combination, for example, a carbomer combined in an approximately 1 :5 to 5: 1 ratio, by weight, with a polyethylene oxide.
  • the present dosage unit contain only active agent and polymeric carrier. However, it may be desirable in some cases to include one or more additional components.
  • a lubricant may be included to facilitate the process of manufacturing the dosage units; lubricants may also optimize erosion rate and drug flux. If a lubricant is present, it will represent on the order of 0.01 wt.% to about 2 wt.%, preferably about 0.01 wt.%) to 0.5 wt,%, of the dosage unit.
  • Suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, sodium stearylfumarate, talc, hydrogenated vegetable oils and polyethylene glycol.
  • modulating the particle size of the components in the dosage unit and/or the density of the unit can provide a similar effect—i.e., improved manufacturability, and optimization of erosion rate and drug flux—without addition of a lubricant.
  • Other components may also be incorporated into the buccal dosage unit; however, it must be emphasized that such components are neither required nor preferred.
  • additional optional components include, for example, one or more disintegrants, diluents, binders, enhancers, or the like.
  • disintegrants examples include, but are not limited to, cross-linked polyvinylpyrrolidones, such as crospovidone (e.g., Polyplasdone® XL, which may be obtained from GAF), cross-linked carboxylic methylcelluloses, such as croscarmelose (e.g., Ac-di-sol®, which may be obtained from FMC), alginic acid, and sodium carboxymethyl starches (e.g., Explotab®, which may be obtained from Edward Medell Co., Inc.), methylcellulose, agar bentonite and alginic acid.
  • cross-linked polyvinylpyrrolidones such as crospovidone (e.g., Polyplasdone® XL, which may be obtained from GAF)
  • cross-linked carboxylic methylcelluloses such as croscarmelose (e.g., Ac-di-sol®, which may be obtained from FMC)
  • alginic acid e.g.,
  • Suitable diluents are those which are generally useful in pharmaceutical formulations prepared using compression techniques, e.g., dicalcium phosphate dihydrate (e.g., Di-Tab®, which may be obtained from Stauffer), sugars that have been processed by cocrystallization with dextrin (e.g., co- crystallized sucrose and dextrin such as Di-Pak®, which may be obtained from Amstar), lactone, calcium phosphate, cellulose, kaolin, mannitol, sodium chloride, dry starch, powdered sugar and the like. Binders, if used, are those that enhance adhesion.
  • dicalcium phosphate dihydrate e.g., Di-Tab®, which may be obtained from Stauffer
  • dextrin e.g., co- crystallized sucrose and dextrin such as Di-Pak®, which may be obtained from Amstar
  • lactone e.g., co- crystallized sucrose and dextrin such
  • binders include, but are not limited to, starch, gelatin and sugars such as sucrose, dextrose, molasses, and lactose.
  • Permeation enhancers may also be present in the novel dosage units in order to increase the rate at which the active agent passes through the buccal mucosa.
  • permeation enhancers include, but are not limited to, polyethylene glycol monolaurate (“PEGML”), glycerol monolaurate, lecithin, the 1 -substituted azacycloheptan-2-ones, particularly 1 - «-dodecylcyclaza-cycloheptan-2-one (available under the trademark Azone® from Nelson Research & Development Co., Irvine, CA), lower alkanols (e.g., ethanol), SEP A® (available from Macrochem Co., Lexington, MA), cholic acid, taurocholic acid, bile salt type enhancers, and surfactants such as Tergitol®, Nonoxynol- 9® and TWEEN-80®.
  • PGML polyethylene glycol monolaurate
  • glycerol monolaurate glycerol monolaurate
  • lecithin the 1 -substituted azacycloheptan-2-ones, particularly 1 - «-d
  • compositions of the invention do not contain permeation enhancers.
  • Flavorings are not typically needed in the present drug dosage units, as the active agents do not, in general, have any taste. If for some reason a flavoring is desired, any suitable flavoring may be used, e.g., mannitol, lactose or artificial sweeteners such as aspartame.
  • Coloring agents may be added, although again, such agents are not required. Examples of coloring agents include any of the water soluble FD&C dyes, mixtures of the same, or their corresponding lakes.
  • the present dosage units may be formulated with one or more preservatives or bacteriostatic agents, e.g., methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride, or the like.
  • preservatives or bacteriostatic agents e.g., methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride, or the like.
  • the present dosage units may be used to deliver a single active agent or two or more active agents in combination.
  • each active agent may be delivered using an individual buccal dosage unit, with the buccal dosage units then used in combination.
  • the active agents are combined in a single buccal dosage unit.
  • the dosage unit of the invention is compositionally a substantially homogeneous, substantially uniform formulation.
  • substantially uniform is meant that the dosage unit is not coated, does not have a backing, and does not contain a plurality of layers or other types of discrete segments. Rather, the substance of the dosage unit is similar throughout, so that the unit is essentially “monolithic” in nature.
  • a method for administering a pharmacologically active agent to a mammalian individual.
  • the method generally comprises buccally administering the agent by affixing a dosage unit as described herein to the buccal mucosa of the individual and allowing the dosage unit to remain in place until erosion thereof— and thus drug delivery— is complete.
  • Administration of an active agent in this way is useful in a variety of contexts, as will be readily appreciated by those skilled in the art.
  • the buccal administration of an androgenic agent using the dosage units of the invention may be used in hormone replacement therapy, particularly male hormone replacement therapy, in male contraception, in the treatment of androgen-responsive disorders such as hypogonadism, and in the treatment of male sexual dysfunction.
  • Hormone replacement therapy is generally called for in male individuals for whom testicular steroid production (e.g., testosterone) has been altered.
  • testicular steroid production e.g., testosterone
  • conditions associated with decreased or absent endogenous testosterone such as primary hypogonadism (congenital or acquired) or secondary hypogonadism (again, congenital or acquired) may be treated by the methods and compositions defined herein.
  • Alteration in testicular steroid production can be caused by, for example, hypothalamic-pituitary defects or testicular defects.
  • hypothalamic-pituitary defects causing altered steroid production include, but are not limited to, panhypopituitarism, hypogonadotropic hypogonadism, Cushing's syndrome, Kolman's syndrome hyperprolactinemia, and hemochromatosis.
  • testicular defects causing altered steroid production include, but are not limited to, developmental and structural defects, such as Klinefelter's syndrome and XX male syndrome.
  • Examples of acquired testicular defects resulting in altered steroid production include, but are not limited to, viral orchitis, testicular failure, ablation or atrophy due to surgery, radiation, or thermal or physical testicular trauma, drugs (e.g., spironolactone, alcohol, ketoconazole, cyclophosphamide), autoimmunity, granulomatous disease, androgen resistance, and systemic disease (e.g., liver disease, renal failure, Sickle cell disease, neurological disease,).
  • the method and drug dosage units of the invention can be used to treat or inhibit the symptoms of osteoporosis, dry eye, or the wasting syndrome accompanying AIDS (e.g., unintentional weight loss, decrease in lean body mass).
  • the buccal dosage unit will contain an androgenic agent in an amount suitable for providing hormone replacement therapy to a male in need of such treatment.
  • the dosage unit is capable of delivering about 4 to about 10 mg of the selected androgen, preferably testosterone, over a predetermined time period, typically in the range of about 4 hours to about 24 hours.
  • the buccal dosage unit will contain approximately 40 wt.% to 80 wt.%) active agent, preferably on the order of 50 wt.% to 75 wt.%> active agent.
  • a preferred buccal dosage unit of the invention incorporates testosterone, or a testosterone ester such as testosterone enanthate, testosterone propionate or testosterone cypionate, while in a particularly preferred embodiment the buccal dosage unit contains testosterone er se.
  • a method is also provided for treating androgen-responsive disorders (such as hypogonadism). Administration of the buccal dosage unit is carried out within the context of a dosing regimen so that a therapeutically effective amount of the active agent is delivered to mitigate or substantially prevent the symptoms associated with the androgen-responsive disorder in the individual being treated.
  • An additional method involves the use of the buccal dosage units to deliver an androgenic agent in the treatment of male sexual dysfunction, particularly erectile dysfunction, and more particularly vasculogenic erectile dysfunction.
  • the dosage and administration period will vary depending on the individual, the severity of sexual dysfunction; however, in general, the preferred dosage and treatment regimen is as described above for hormone replacement therapy and the like. That is, for testosterone, it is generally preferred that the daily dosage be in the range of 4 mg to 10 mg, with, again, 12-hour dosage units particularly preferred.
  • the buccal dosage units are preferably used consecutively so that administration of the active agents is substantially continuous.
  • Buccal drug administration according to the invention provides highly effective male hormone replacement therapy. That is, the disadvantages of gastrointestinal degradation and first-past inactivation of the active agents are avoided. At the same time, the side effects normally expected and encountered with conventional hormone replacement are minimized or eliminated.
  • the buccal dosage units are administered so that the male's natural circadian levels are simulated, with peak plasma testosterone levels occurring at about 6 a.m. to 8 a.m., decreasing thereafter for about 16-18 hours, and then increasing until the daily high is again reached.
  • the buccal dosage units of the present invention may be in the form of tablets made by conventional compression or molding methods. See, e.g., Remington's Pharmaceutical Sciences, 18 th edition, (Easton, PA: Mack Publishing Co., 1990).
  • the dosage units of the present invention are prepared by mixing the components together and compressing the mixture, at a slightly elevated temperature, into tablet form.
  • the erosion rate of the dosage unit, and thus the rate of drug delivery is controlled by three factors: the pressure used to make the tablets, and thus the tablets' density; the carrier selected, as alluded to above; and the carrier-to-drug ratio. Pressure, carrier and carrier-to-drug ratio may thus be varied to obtain shorter acting or longer-lived dosage units.
  • Preferred pressure for preparing the present dosage unit by compaction is in the range of approximately 500 to 2000 psi.
  • the dosage units herein may have any of the conventional shapes, for example, lozenges, disks, wafers, tablets or the like.
  • One possible configuration is a conventional tablet shape as shown in Figure 4, with the dosage unit indicated generally at 10, the pharmaceutical composition er se shown at 12, and the dosage unit's two parallel substantially planar surfaces shown at 14 and 16; either surface can be used to affix the unit to the buccal mucosa.
  • FIG. 5 A more preferred configuration is shown in Figure 5, wherein the dosage unit is shown generally at 18 with the composition at 20, and the two opposing concave surfaces at 22 and 24; the opposing concave surfaces allow for a suction effect and improve adhesion of the unit to the mucosal tissue.
  • Figure 6 A less preferred configuration is shown in Figure 6, wherein the dosage unit shown generally at 26, containing pharmaceutical composition 28, has opposing convex surfaces 30 and 32.
  • the dosage unit should have dimensions which fit conveniently into the buccal cavity, and, as emphasized elsewhere herein, is preferably quite compact.
  • suitable dimensions for the dosage unit are 2 mm to about 5 mm in diameter, preferably not exceeding about 5 mm in diameter, and about 0.3 to about 2 mm in thickness, preferably about 0.5 to 1.5 mm in thickness, most preferably about 0.5 to 1.1 mm in thickness.
  • the total weight of the dosage unit may be from about 5 mg to about 20 mg, preferably 10 mg to about 15 mg.
  • the preferred position for placement of the dosage unit in the buccal cavity, as illustrated in Figure 7, is in the oral vestibule, generally indicated at 40, on the anterior surface 42 of the gum, between the marginal gingiva 44 and the reflexion of the mucosa from the lips to the gums 46, i.e., the dosage unit 48 is preferably attached to the alveolar mucosa 50, between the two bicuspids 52 and 54 and slightly to one side of the medial plane defined thereby.
  • Such positioning places the dosage unit in contact with the mucosa on the internal surface of the lips 56 as well as the alveolar mucosa 50.
  • Such placement provides advantages for optimal drug delivery.
  • the dosage unit when so positioned, is out of the salivary flow path and is less likely to detach from the gum during eating or drinking. Being out of the salivary flow path allows optimal direct transmucosal delivery of the active agents, any saliva that contacts the unit resulting not in dissolution of the active agent but, primarily, in softening the carrier. In addition, positioning the dosage unit as described minimizes mobility of the active agent in the mouth. Furthermore, the dosage unit will be in contact with both the alveolar mucosa and the internal mucosal surface of the lips, resulting in hydrolysis of the carrier, and thus absorption of the active agents through mucosa, on both sides of the tablet.
  • the invention also encompasses a kit for patients to carry out the aforementioned methods.
  • the kit contains the drug to be administered in a buccal dosage unit (e.g., as shown in Figure 4), a sealed container housing the dosage unit prior to use, and written instructions for drug administration.
  • the present invention thus provides a new drug delivery platform for administering pharmacologically active agents.
  • a number of important and heretofore unrealized advantages have now been achieved: -the dosage units of the invention are highly compact, minimizing the possibility of patient discomfort;
  • the dosage units adhere well to the buccal mucosa and the potential for detachment during drug delivery is minimal; the dosage units enable administration of therapeutically effective amounts of potent active agents that have low oral bioavailability;
  • the dosage units are efficient in that bio-erosion, i.e., hydrolysis, occurs on both sides of the buccal tablet following affixation to the buccal mucosa;
  • the dosage units completely hydrolyze, leaving no backing layer in the mouth; -duration of the drug delivery period is easy to control by simply adjusting the compaction pressure during manufacture and/or the size of the dosage unit; and -with delivery of an androgenic agent, particularly testosterone, the dosage unit enables ready simulation of a mammalian male's circadian plasma levels, in turn facilitating treatment of male sexual dysfunction and optimizing male hormone replacement therapy.
  • Buccal dosage units weighing approximately 10 mg to 15 mg each and containing testosterone as the active agent were prepared using a tablet direct press, as follows.
  • Testosterone (USP, micronized, Pharmacia, Upjohn) 29.8% Polyethylene oxide (Polyox® WSR-303, Union Carbide)
  • All components i.e., testosterone, polyethylene oxide and magnesium stearate, as set forth in the above table
  • the individual dosage units were then made by applying approximately 10 to 15 mg of the mixture into the punch die of the tablet press, and compressing the mixed components using a pressure in the range of approximately 500 to 2000 psi. Tablets having a diameter of approximately 4 mm and a height of 1 mm were prepared. The tablet was removed from the punch die and the weight and dimensions of the tablet were measured.
  • Carbomer (Carbopol®, NF)
  • Testosterone was administered to a male individual using a buccal dosage unit described in Example 1 (Tl-1). Plasma samples were collected and analyzed for total testosterone, free testosterone, dihydrotestosterone and estradiol levels prior to treatment and at four-hour intervals after the start of treatment. The method was repeated using the same individual and the buccal dosage unit prepared as in Example 2 (T2-1). Finally, the method was repeated using the same individual and a placebo.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une unité posologique orale simple et compacte destinée à l'administration d'un principe actif pharmacologique à un mammifère. Cette unité posologique orale comprend le principe actif à administrer, un excipient polymère à bioérosion capable de libérer un agent androgène pendant une période définie, et de préférence, un lubrifiant tel que le stéarate de magnésium. Ces unités posologiques se prêtent particulièrement à l'administration de médicaments présentant une faible biodisponibilité orale tout en étant puissants, ce qui fait qu'on peut les administrer en petites quantités, c'est à dire à faibles doses en utilisant de tels systèmes compacts. L'invention concerne également des procédés d'administration de principes actifs en utilisant de telles unités posologiques.
PCT/US2000/001534 1999-01-26 2000-01-21 Unite posologique compacte pour administration orale de principe actif pharmacologique WO2000042959A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU26236/00A AU2623600A (en) 1999-01-26 2000-01-21 Compact dosage unit for buccal administration of a pharmacologically active agent
CA002359582A CA2359582A1 (fr) 1999-01-26 2000-01-21 Unite posologique compacte pour administration orale de principe actif pharmacologique
EP00904484A EP1162929A4 (fr) 1999-01-26 2000-01-21 Unite posologique compacte pour administration orale de principe actif pharmacologique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/236,892 US6284262B1 (en) 1999-01-26 1999-01-26 Compact dosage unit for buccal administration of a pharmacologically active agent
US09/236,892 1999-01-26

Publications (1)

Publication Number Publication Date
WO2000042959A1 true WO2000042959A1 (fr) 2000-07-27

Family

ID=22891430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001534 WO2000042959A1 (fr) 1999-01-26 2000-01-21 Unite posologique compacte pour administration orale de principe actif pharmacologique

Country Status (5)

Country Link
US (1) US6284262B1 (fr)
EP (1) EP1162929A4 (fr)
AU (1) AU2623600A (fr)
CA (1) CA2359582A1 (fr)
WO (1) WO2000042959A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
EP1978927A1 (fr) * 2006-01-24 2008-10-15 Bayer Schering Pharma Aktiengesellschaft Formes galeniques filmogenes pour application dans la cavite buccale (plaquette)
EP2919767A4 (fr) * 2012-11-14 2016-07-20 Abon Pharmaceuticals Llc Système d'administration d'un médicament par voie orale transmuqueuse
WO2023203173A1 (fr) * 2022-04-22 2023-10-26 Prolevi Bio Ab Compositions pour la libération modifiée d'ingrédients actifs

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
PL345955A1 (en) * 1998-06-11 2002-01-14 Endorech PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL
US6943267B1 (en) 2001-08-24 2005-09-13 Utah State University Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
EP1596881B1 (fr) * 2003-02-07 2008-12-10 Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung Utilisation de la gonadotrophine chorionique humaine dans le traitement des symptomes causes par l'endometriose
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US20060275364A1 (en) * 2005-05-26 2006-12-07 Ahmed Salah U Flexible Solid Dosage Forms and Methods of Making and Using the Same
US7605122B2 (en) * 2005-07-29 2009-10-20 Millennium Medical Spa Human chorionic gonadotropin (hCG) formulations for facilitating weight loss and body contouring
US8124095B2 (en) 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
CN103550136B (zh) 2006-07-21 2016-04-13 生物递送科学国际公司 吸收增强的经粘膜递送装置
EP2051734B1 (fr) * 2006-08-18 2016-10-05 Armagen Technologies, Inc. Agents pour barrière hémato-encéphalique
KR20090093792A (ko) * 2006-12-28 2009-09-02 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 피부 조직 개선재 및 그 제조 방법
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
KR101306537B1 (ko) 2008-06-04 2013-09-09 콜게이트-파아므올리브캄파니 캐비테이션 시스템을 가진 구강 관리기구
US20100098693A1 (en) * 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
EP2408474B1 (fr) 2009-03-18 2019-06-26 Armagen, Inc. Compositions et procédés pour le transport de protéines de fusion igg-récepteur leurre à travers la barrière hémato-encéphalique
AU2010295883B2 (en) * 2009-09-16 2015-08-20 Philip Morris Products Sa Improved device and method for delivery of a medicament
HUE044865T2 (hu) 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
KR101773636B1 (ko) 2009-11-19 2017-09-01 솔리스 바이오다인 폴리펩티드 안정성 및 활성을 증가시키는 조성물 및 관련된 방법
EA201991223A1 (ru) 2011-08-18 2019-10-31 Не вызывающие зависимость мукоадгезивные устройства для доставки бупренорфина
JP6266529B2 (ja) 2011-12-02 2018-01-24 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおけるアリールスルファターゼａ活性を増加するための方法および組成物
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
JP6692293B2 (ja) 2013-07-22 2020-05-13 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおける酵素活性を増大するための方法および組成物
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CN107847722B (zh) 2015-05-06 2021-05-18 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5053032A (en) * 1989-07-14 1991-10-01 Barclay Brian L Method of signalling a patient during buccal agent delivery

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704285A (en) 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4877774A (en) 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
US5004601A (en) * 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5135752A (en) 1988-10-14 1992-08-04 Zetachron, Inc. Buccal dosage form
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5458884A (en) * 1992-09-10 1995-10-17 Britton; Peter Bioerodible device for administering active ingredients
US5639743A (en) 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5053032A (en) * 1989-07-14 1991-10-01 Barclay Brian L Method of signalling a patient during buccal agent delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BHASIN S. ET AL.: "Emerging issues in androgen replacement therapy", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 82, no. 1, 1997, pages 3 - 8, XP002927166 *
See also references of EP1162929A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
EP1978927A1 (fr) * 2006-01-24 2008-10-15 Bayer Schering Pharma Aktiengesellschaft Formes galeniques filmogenes pour application dans la cavite buccale (plaquette)
EP2919767A4 (fr) * 2012-11-14 2016-07-20 Abon Pharmaceuticals Llc Système d'administration d'un médicament par voie orale transmuqueuse
AU2017203861B2 (en) * 2012-11-14 2018-08-16 Abon Pharmaceuticals, Llc Oral Transmucosal Drug Delivery System
US10821118B2 (en) 2012-11-14 2020-11-03 Abon Pharmaceuticals Llc Oral transmucosal drug delivery system
WO2023203173A1 (fr) * 2022-04-22 2023-10-26 Prolevi Bio Ab Compositions pour la libération modifiée d'ingrédients actifs

Also Published As

Publication number Publication date
CA2359582A1 (fr) 2000-07-27
EP1162929A4 (fr) 2002-06-26
US6284262B1 (en) 2001-09-04
EP1162929A1 (fr) 2001-12-19
AU2623600A (en) 2000-08-07

Similar Documents

Publication Publication Date Title
US6284262B1 (en) Compact dosage unit for buccal administration of a pharmacologically active agent
US6200593B1 (en) Contraceptive method employing buccal delivery of steroidal active agents
AU2004220498B2 (en) Uses and formulations for transdermal or transmucosal application of active agents
US6180682B1 (en) Buccal drug delivery system for use in male contraception
US7470433B2 (en) Formulations for transdermal or transmucosal application
JP5184727B2 (ja) 女性への非経口アンドロゲンステロイドの投与
US7226910B2 (en) Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists
US8338400B2 (en) Methods and apparatus for transdermal or transmucosal application of testosterone
US20020013304A1 (en) As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20050070516A1 (en) As-needed administration of an androgenic agent to enhance female desire and responsiveness
JP2879695B2 (ja) 口腔内粘膜付着性フィルム製剤
JP2007537178A (ja) 経口投与のためのフィルム型エストリオール含有医薬
US20120282340A1 (en) Drug delivery system
CN1997357A (zh) 透皮或透粘膜应用活性剂的用途和制剂
AU2002313709A1 (en) As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
MXPA98003137A (en) Mouth-release of insulinotropic peptides like gluca

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2359582

Country of ref document: CA

Ref country code: CA

Ref document number: 2359582

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000904484

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000904484

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 2000904484

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000904484

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载